Search Results - "CHURG, Andrew"

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification by Galateau-Salle, Francoise, Churg, Andrew, Roggli, Victor, Travis, William D

“…A new World Health Organization (WHO) Classification of Tumors of the Pleura has recently been published. While the histologic classification of pleural…”
Get more information

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group by Husain, Aliya Noor, Colby, Thomas V, Ordóñez, Nelson G, Allen, Timothy Craig, Attanoos, Richard Luther, Beasley, Mary Beth, Butnor, Kelly Jo, Chirieac, Lucian R, Churg, Andrew M, Dacic, Sanja, Galateau-Sallé, Françoise, Gibbs, Allen, Gown, Allen M, Krausz, Thomas, Litzky, Leslie Anne, Marchevsky, Alberto, Nicholson, Andrew G, Roggli, Victor Louis, Sharma, Anupama K, Travis, William D, Walts, Ann E, Wick, Mark R

“…- Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. - To provide updated, practical guidelines for the pathologic diagnosis…”
Get full text

CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations by Salisbury, Taylor, Churg, Andrew

“…The separation of benign from malignant mesothelial cells is often a challenging problem. Some studies have suggested that immunohistochemical staining of…”
Get full text

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung by Berg, Kyra B, Churg, Andrew

“…The separation of sarcomatoid and desmoplastic malignant mesotheliomas from sarcomatoid carcinomas of the lung metastatic to the pleura may be difficult, since…”
Get full text

The separation of benign and malignant mesothelial proliferations by Churg, Andrew, Galateau-Salle, Francoise

“…The separation of benign from malignant mesothelial proliferations is crucial to patient management but is often a difficult problem for the pathologist. To…”
Get full text

HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma by Naso, Julia R., Tsuji, Shoutaro, Churg, Andrew

“…Malignant mesothelioma can be difficult to distinguish from other malignancies, particularly non–small cell lung carcinomas (NSCLCs), without…”
Get full text

Animal models of chronic obstructive pulmonary disease by Wright, Joanne L, Cosio, Manuel, Churg, Andrew

“…The mechanisms involved in the genesis of chronic obstructive pulmonary disease (COPD) are poorly defined. This area is complicated and difficult to model…”
Get more information

MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma by Chapel, David B., Schulte, Jefree J., Berg, Kyra, Churg, Andrew, Dacic, Sanja, Fitzpatrick, Carrie, Galateau-Salle, Francoise, Hiroshima, Kenzo, Krausz, Thomas, Le Stang, Nolwenn, McGregor, Stephanie, Nabeshima, Kazuki, Husain, Aliya N.

“…Ancillary studies facilitate accurate diagnosis of morphologically challenging mesothelial proliferations. The current diagnostic algorithm proceeds from BAP1…”
Get full text

The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification by Sauter, Jennifer L, Dacic, Sanja, Galateau-Salle, Francoise, Attanoos, Richard L, Butnor, Kelly J, Churg, Andrew, Husain, Aliya N, Kadota, Kyuichi, Khoor, Andras, Nicholson, Andrew G, Roggli, Victor, Schmitt, Fernando, Tsao, Ming-Sound, Travis, William D

“…Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural…”
Get more information

BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations by Sheffield, Brandon S, Hwang, Harry C, Lee, Anna F, Thompson, Kim, Rodriguez, Stephanie, Tse, Christopher H, Gown, Allen M, Churg, Andrew

“…A variety of immunohistochemical (IHC) stains have been proposed to mark either benign or malignant mesothelial proliferations. Loss of the p16 tumor…”
Get full text

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens by Hwang, Harry C, Sheffield, Brandon S, Rodriguez, Stephanie, Thompson, Kim, Tse, Christopher H, Gown, Allen M, Churg, Andrew

“…The diagnosis of malignant mesothelioma in effusion cytology specimens is controversial. BAP1 immunohistochemistry and p16 fluorescence in situ hybridization…”
Get full text

Malignant mesothelioma in situ: morphologic features and clinical outcome by Churg, Andrew, Galateau-Salle, Francoise, Roden, Anja C., Attanoos, Richard, von der Thusen, Jan H., Tsao, Ming-Sound, Chang, Nina, De Perrot, Marc, Dacic, Sanja

“…The existence of an in situ phase of malignant mesothelioma has long been postulated but until recently has been impossible to prove. Here we describe ten…”
Get full text

Mechanisms of cigarette smoke-induced COPD: insights from animal models by Churg, Andrew, Cosio, Manuel, Wright, Joanne L

“…Cigarette smoke-induced animal models of chronic obstructive pulmonary disease support the protease-antiprotease hypothesis of emphysema, although which cells…”
Get more information

Usefulness of methylthioadenosine phosphorylase and BRCA‐associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens by Berg, Kyra B., Churg, Andrew M., Cheung, Simon, Dacic, Sanja

“…Background The separation of benign from malignant mesothelial proliferations on effusion cytology can be difficult. Loss of methylthioadenosine phosphorylase…”
Get full text

Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease by Tam, Anthony, Churg, Andrew, Wright, Joanne L, Zhou, Steven, Kirby, Miranda, Coxson, Harvey O, Lam, Stephen, Man, S F Paul, Sin, Don D

“…After adjustment for the amount of smoking, women have a 50% increased risk of chronic obstructive pulmonary disease (COPD) compared with men. The anatomic…”
Get full text

Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma by Naso, Julia R., Cheung, Simon, Ionescu, Diana N., Churg, Andrew

“…The separation of malignant mesothelioma from non–small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled…”
Get full text

Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis by Wright, Joanne L., Churg, Andrew, Hague, Cameron J., Wong, Alyson, Ryerson, Christopher J.

“…Accurate separation of idiopathic pulmonary fibrosis from fibrotic (chronic) hypersensitivity pneumonitis is crucial to patient management, but is frequently a…”
Get full text

EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach by Nicholson, Andrew G, Sauter, Jennifer L, Nowak, Anna K, Kindler, Hedy L, Gill, Ritu R, Remy-Jardin, Martine, Armato, 3rd, Samuel G, Fernandez-Cuesta, Lynnette, Bueno, Raphael, Alcala, Nicolas, Foll, Matthieu, Pass, Harvey, Attanoos, Richard, Baas, Paul, Beasley, Mary Beth, Brcic, Luka, Butnor, Kelly J, Chirieac, Lucian R, Churg, Andrew, Courtiol, Pierre, Dacic, Sanja, De Perrot, Marc, Frauenfelder, Thomas, Gibbs, Allen, Hirsch, Fred R, Hiroshima, Kenzo, Husain, Aliya, Klebe, Sonja, Lantuejoul, Sylvie, Moreira, Andre, Opitz, Isabelle, Perol, Maurice, Roden, Anja, Roggli, Victor, Scherpereel, Arnaud, Tirode, Frank, Tazelaar, Henry, Travis, William D, Tsao, Ming-Sound, van Schil, Paul, Vignaud, Jean Michel, Weynand, Birgit, Lang-Lazdunski, Loic, Cree, Ian, Rusch, Valerie W, Girard, Nicolas, Galateau-Salle, Francoise

“…Molecular and immunologic breakthroughs are transforming the management of thoracic cancer, although advances have not been as marked for malignant pleural…”
Get more information

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma by Chiu, Kenrry, Lee, Lawrence, Cheung, Simon, Churg, Andrew M.

“…Immunohistochemistry (IHC) is used to help differentiate pleural mesothelioma from pulmonary adenocarcinoma in pleural biopsies and cytology specimens of…”
Get full text

BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas by Hwang, Harry C, Pyott, Shawna, Rodriguez, Stephanie, Cindric, Ashlie, Carr, April, Michelsen, Carmen, Thompson, Kim, Tse, Christopher H, Gown, Allen M, Churg, Andrew

“…The separation of sarcomatous and desmoplastic mesotheliomas from benign organizing pleuritis can be morphologically very difficult. Deletion of p16 (CDKN2A)…”
Get full text